ASND – ascendis pharma a/s - american depositary shares (US:NASDAQ)
Stock Stats
News
Ascendis Pharma A/S (NASDAQ:ASND) had its price target raised by analysts at Bank of America Corporation from $246.00 to $260.00. They now have a "buy" rating on the stock.
RBC Maintains Outperform Rating on Ascendis Pharma (ASND) Amid Growth Targets [Yahoo! Finance]
Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Ascendis Pharma A/S (NASDAQ:ASND) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Ascendis: Why I'm Skeptical On Takeover Rumors, Long-Term Targets [Seeking Alpha]
Form 6-K Ascendis Pharma A/S For: Jan 14
Form 144 Ascendis Pharma A/S Filed by: MIKKELSEN JAN MOLLER
Form 6-K Ascendis Pharma A/S For: Jan 12
Form 6-K Ascendis Pharma A/S For: Jan 08
Form 6-K Ascendis Pharma A/S For: Dec 30
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.